the protein cd201 is typically found in blood clots caused by venom, or in fetal loss during pregnancy, according to a 2004 study.
a better understanding of how the genes involved in hscs work will give scientists a better shot at manipulating them for medical use. potential treatments could include sickle cell anemia, hiv, and even some forms of cancer.
using techniques that allowed researchers to assess surface level activity on the cell, and rna sequencing simultaneously, they were able to find that cd201 is a significant target for engraftment potential, the study reads.
engraftment is when the blood forming cells that are received during a transplant start to grow and develop more healthy blood cells.
“altogether, this work has resulted in a detailed blueprint of the most potent blood stem cells and will lead to a better understanding of why these cells have such an extraordinary regenerative capacity,” kim vanuytsel, lead author of the study said. “such insights will allow us to create safer and more efficient therapies for patients suffering from blood disorders.”
the work between boston university and mgh was critical for sharing both resources and information, george murphy, co-senior author of the study said.
“this project is also a shining example of ‘open source biology’ at work where the freely shared information and insights can be harnessed by all for future discovery,” murphy said.
chris arnold is a toronto-based writer.
thank you for your support. if you liked this story, please send it to a friend. every share counts.
share story
share this story
stem cell study identifies genes that may better the odds for people with blood disorders